Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care?

Area of Science:

• Oncology and Molecular Biology
• Genomics and Precision Medicine

Background:

• Hepatocellular carcinoma (HCC) treatment remains challenging.
• The 'omics revolution offers new avenues for personalized HCC management.

Purpose of the Study:

• To explore the integration of 'omics data for improved HCC diagnosis, staging, treatment, and monitoring.
• To highlight novel therapeutic strategies targeting molecular drivers in HCC.
• To combine molecular mechanisms, circulating tumor cells, and radiogenomics for enhanced clinical decision-making.

Main Methods:

• Review and synthesis of current 'omics technologies in cancer research.
• Analysis of the role of circulating tumor cells (CTCs) in HCC.
• Integration of radiogenomic data with molecular profiling.

Main Results:

• 'Omics approaches enable personalized HCC management.
• Targeting specific molecular drivers presents promising therapeutic opportunities.
• Circulating tumor cells and radiogenomics can refine clinical decision-making.

Conclusions:

• Personalized medicine, driven by 'omics, is transforming HCC care.
• Novel therapies targeting molecular pathways are emerging.
• Integrating diverse data streams (molecular, CTCs, radiogenomics) will optimize HCC treatment strategies.